Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 541 to 550 of 1532

TitleReference numberPublishedLast updated
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)TA771
d-Nav insulin management app for type 2 diabetesMIB285
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal)TA762
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitableTA763
Fremanezumab for preventing migraineTA764
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA765
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanomaTA766
Ponesimod for treating relapsing–remitting multiple sclerosisTA767
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA768

Results per page

  1. 10
  2. 25
  3. 50
  4. All